Microambient en la patogènesi i teràpia del limfoma
Publicacions destacades
-
Patient-derived follicular lymphoma spheroids recapitulate lymph node signaling and immune profile uncovering galectin-9 as a novel immunotherapeutic target
Dobano-Lopez, Celia; Valero, Juan Garcia; Araujo-Ayala, Ferran; Nadeu, Ferran; Gava, Fabien;(...)Lopez-Guillermo, Armando; Magnano, Laura; Colomer, Dolors; Bezombes, Christine; Perez-Galan, Patricia.Referència:Blood Cancer Journal 2024.
-
Patient-derived lymphoma spheroids integrating immune tumor microenvironment as preclinical follicular lymphoma models for personalized medicine
Faria, Carla; Gava, Fabien; Gravelle, Pauline; Valero, Juan Garcia; Dobano-Lopez, Celia;(...)Fournie, Jean-Jacques; Ysebaert, Loic; Laurent, Camille; Perez-Galan, Patricia; Bezombes, Christine.Referència:Journal For Immunotherapy Of Cancer 2023.
-
A novel patient-derived 3D model recapitulates mantle cell lymphoma lymph node signaling, immune profile and in vivo ibrutinib responses
Araujo-Ayala, Ferran; Dobano-Lopez, Celia; Valero, Juan Garcia; Nadeu, Ferran; Gava, Fabien;(...)Lopez-Guillermo, Armando; Gine, Eva; Colomer, Dolors; Bezombes, Christine; Perez-Galan, Patricia.Referència:Leukemia 2023.
-
The receptor of the colony-stimulating factor-1 (CSF-1R) is a novel prognostic factor and therapeutic target in follicular lymphoma
Valero, Juan Garcia; Matas-Cespedes, Alba; Arenas, Fabian; Rodriguez, Vanina; Carreras, Joaquim;(...)Cid, Maria C; Campo, Elias; Lopez-Guillermo, Armando; Colomer, Dolors; Perez-Galan, Patricia.Referència:Leukemia 2021.
-
3D Model Characterization by 2D and 3D Imaging in t(14;18)-Positive B-NHL: Perspectives for In Vitro Drug Screens in Follicular Lymphoma
Gava, Fabien; Faria, Carla; Gravelle, Pauline; Valero, Juan G; Dobano-Lopez, Celia;(...)Fournie, Jean-Jacques; Ysebaert, Loic; Laurent, Camille; Perez-Galan, Patricia; Bezombes, Christine.Referència:Cancers 2021.
-
PI3Kδ inhibition reshapes follicular lymphoma-immune microenvironment cross talk and unleashes the activity of venetoclax
Serrat, Neus; Guerrero-Hernandez, Martina; Matas-Cespedes, Alba; Yahiaoui, Anella; Valero, Juan G;(...)Hodson, Daniel J; Lopez-Guillermo, Armando; Colomer, Dolors; Tannheimer, Stacey; Perez-Galan, Patricia.Referència:Blood Advances 2020.
-
Daratumumab displays in vitro and in vivo anti-tumor activity in models of B-cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens
Vidal-Crespo, Anna; Matas-Cespedes, Alba; Rodriguez, Vanina; Rossi, Cedric; Valero, Juan G;(...)Bezombes, Christine; van Bueren, Jeroen Lammerts; Chiu, Christopher; Doshi, Parul; Perez-Galan, Patricia.Referència:Haematologica 2020.
-
The Bruton tyrosine kinase inhibitor CC-292 shows activity in mantle cell lymphoma and synergizes with lenalidomide and NIK inhibitors depending on nuclear factor-κB mutational status
Vidal-Crespo, Anna; Rodriguez, Vanina; Matas-Cespedes, Alba; Lee, Eriong; Rivas-Delgado, Alfredo;(...)Lopez-Guillermo, Armando; Lopez-Guerra, Monica; Roue, GaeL; Colomer, Dolors; Perez-Galan, Patricia.Referència:Haematologica 2017.
-
The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia-Microenvironment Interactions in Chronic Lymphocytic Leukemia
Matas-Cespedes, Alba; Vidal-Crespo, Anna; Rodriguez, Vanina; Villamor, Neus; Delgado, Julio;(...)Wiestner, Adrian; Parren, Paul W H I; Doshi, Parul; van Bueren, Jeroen Lammerts; Perez-Galan, Patricia.Referència:Clinical Cancer Research 2017.
-
Disruption of Follicular Dendritic Cells-Follicular Lymphoma Cross-talk by the Pan-PI3K Inhibitor BKM120 (Buparlisib)
Matas-Cespedes, Alba; Rodriguez, Vanina; Kalko, Susana G; Vidal-Crespo, Anna; Rosich, Laia;(...)Campo, Elias; Roue, Gael; Lopez-Guillermo, Armando; Colomer, Dolors; Perez-Galan, Patricia.Referència:Clinical Cancer Research 2014.